Form 4: MANGOCEUTICALS Director Sells 125,000 Shares

MANGOCEUTICALS, INC. Director Alex P. Hamilton sold 125,000 shares of common stock at a weighted average price of $1.223 per share.

Summary

• Director Alex P. Hamilton of MANGOCEUTICALS, INC. (MGRX) sold 125,000 shares of common stock.
• The transaction occurred on November 19, 2025.
• The shares were sold at a weighted average price of $1.223 per share, with prices ranging from $1.195 to $1.2465.
• Following the sale, Mr. Hamilton directly owns 3,334 shares of MANGOCEUTICALS, INC. common stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 4

Explanation: The sale of a significant portion of a director's holdings, even under a 10b5-1 plan, generally carries a negative sentiment as it reduces insider alignment and can be perceived as a lack of confidence. However, the pre-planned nature mitigates some of the immediate negative implications compared to an unplanned sale.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-arranged sale for personal financial planning rather than a reaction to immediate negative company news.

Negatives

• A director selling a significant portion of their holdings (125,000 shares, reducing their stake to 3,334 shares) could be perceived negatively by investors, potentially signaling a lack of confidence or a need for liquidity.

Future Outlook

NA

Industry Context

Insider sales, particularly by directors, are routinely monitored by investors as they can sometimes provide insights into management's perception of the company's future prospects or valuation. The use of a 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to immediate market conditions, which can mitigate some of the negative interpretations of an insider sale.

Comparison to Industry Standards

• Insider selling is a common occurrence across all industries, often for personal financial planning, diversification, or tax purposes.
• The sale of 125,000 shares by a director, reducing their direct holdings to 3,334 shares, represents a significant reduction in their stake, a metric often scrutinized by investors for potential signals about future company performance.
• Compared to other insider transactions, the use of a Rule 10b5-1 plan is a standard practice for executives and directors to sell shares systematically while adhering to insider trading regulations and avoiding accusations of trading on material non-public information.

Related Party Transactions

• Director Alex P. Hamilton, a related party, sold 125,000 shares of MANGOCEUTICALS, INC. common stock.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a negative signal, potentially leading to downward pressure on the stock price due to perceived reduced insider confidence.
• Management/Employees: Could potentially impact morale if interpreted as a lack of confidence from a director, though the 10b5-1 plan context may temper this.

Key Dates

Recommendation

While a significant insider sale can be a negative signal, the transaction was executed under a pre-arranged 10b5-1 plan, which suggests a planned liquidity event rather than a reaction to new negative information. Investors should monitor future insider activity and company performance, but this single event, while notable, does not immediately warrant a 'sell' given the 10b5-1 context. A 'hold' recommendation allows for further observation.

Keywords

MANGOCEUTICALS, MGRX, Alex P. Hamilton, Insider Sale, Form 4, Director Sale, Stock Transaction, Equity Sale, 10b5-1 Plan